Академический Документы
Профессиональный Документы
Культура Документы
SUMANA MAITI
INVASIVE DISEASE
1. BLEEDING --- postmenopausal, metrorrhagia, menorrhagia, post coital
bleeding.
2. PAIN in the pelvis or hypogastrium 3. URINARY Symptoms 4. RECTAL Symptoms 5. DISTANT SITE SPECIFIC METASTATIC MANIFESTATIONS
a. LYMPHATIC SPREAD --- to supraclavicular lns, para-aortic lymphadenopathy (non specific abdominal ymptoms) b. HEMATOGENOUS SPREAD---- to lungs (cough, respiratory distress, in 21% of patients in metastatic setting) ---- bone pain
2
1) Palpation, inspection, FIGO GUIDELINES 2) Colposcopy, 3) Endocervical curettage, 4)Hysteroscopy, 5) Cystoscopy, 6)Proctoscopy 7) Punch biopsy (edge of gross tumour,4quadrants), and
Radiologic examination
1) Chest Xray of the lungs 2)Barium enema 3) intravenous urography,.
5
Findings of bullous edema or malignant cell in cytologic washings from the urinary bladder are not sufficient to diagnose bladder involvement.
Conization:
Removes a coneshaped piece of tissue Often allows for diagnosis and treatment Performed with local anesthesia in the office or under general anesthesia in the operating room
9
STAGING --- FIGO STAGING 1) FIGO staging was based on anatomical compartmental spread of cervical cancer. 2) No inclusion of lymph nodal status 3) LVI not included because pathologists do not agree on status on presence of LVI 4) MRI, CT and PET Scan not included in formal staging.
10
STAGING
11
12
TNM
Dual system --- clinical (pretreatment) & post treatment (pathological) Separate classification for T NM, Clinical and pathological MRI, CT SCAN, ---Alters the clinical classification Definitive nodal classification
FIGO
FIGO uses clinical --essentially anatomical Only stages and substages (I,II,III, IV, IA, IB) No role of optional investigations for FIGO clinical staging No role of LVSI , nodal status
13
1) 2) 3) 4)
14
TREATMENT-Carcinoma in situ
Conservative-Theraputic conization,Laser therapy,Cryotherapy. Irradiation. Surgery-TAH with or without small vaginal calf.
IA----- Invasive carcinoma which can be diagnosed only by microscopy, with deepest invasion 5 mm and largest extension 7 mm IA1 ----- Measured stromal invasion of 3.0 mm in depth and extension of 7.0 mm
Stage IA1---- SURGERY ---- RADIOTHERAPY RESTRICTED TO PATIENTS WHO ARE NOT CANDIDATES OF SURGERY THEN WHO ARE THE CANDIDATES OF SURGERY ???? OPTIONS 1) SIMPLE HYSTERECTOMY (provided there is no LVSI) 2) CONIZATION 3) CLOSE OBSERVATION 4) BRACHYTHERAPY http://icmr.nic.in/guide/cancer/CcMG.pdf
There is no need to remove pelvic lymph nodes when treating IA1
16
IA2 ----- Measured stromal invasion of 3.0 mm and not 5.0 mm with an extension of not 7.0 mm
OPTIONS SURGERY ---- RADIOTHERAPY RESTRICTED TO PATIENTS WHO ARE NOT CANDIDATES OF SURGERY THEN WHO ARE THE CANDIDATES OF SURGERY ????
1. 2. 3.
total abdominal or modified radical hysterectomy, Vaginal trachelectomy with pelvic lymphadenectomy. Intracavitary radioactive sources alone (6,500 to 8,000 mgh, 60 to 75 Gy to point A, in two LDR insertions, respectively). With HDR brachytherapy the dose is approximately 36 to 45 Gy in 6 to 8 fractions, depending on tumor volume and depth of stromal invasion.
If fertility is desired, options are: i large cone biopsy plus extra peritoneal or laparoscopic pelvic lymphadenectomy, ii radical trachelectomy and extra peritoneal or laparoscopic pelvic lymphadenectomy.
17
FIGO stage
IB Clinically visible lesions limited to the cervix uteri or pre-clinical cancers greater than stage IA . IB1 Clinically visible lesion 4.0 cm in greatest dimension
TREATMENT OPTIONS ----1) Radical hysterectomy (type III) with pelvic node dissection 2) Radical Radiation Therapy [ EBRT + BRACHYTHERAPY] [ DOSE --- 80 Gy LDR equivalent dose to Point A]
18
Stage IB2 and IIA: IB2 Clinically visible lesion N4.0 cm in greatest dimension Stage II Cervical carcinoma invades beyond the uterus, but not to the pelvicwall or to the lower third of the vagina IIA Without parametrial invasion IIA1 Clinically visible lesion 4.0 cm in greatest dimension IIA2 Clinically visible lesion N4 cm in greatest dimension
The treatment options include 1. Radical hysterectomy (Type III) and bilateral pelvic lymphadenectomy 2. Radical Radiation therapy (External plus intracavitary). 3. Concomitant chemo radiation (Radiation therapy + Weekly Cisplatin).
19
2) PROGNOSTIC FACTORS A. HIGH RISK FACTORS FOR RECURRNT TUMOURS (recurrence rate 40% within 3 years) 1) POSITIVE or CLOSE MARGINS 2) POSITIVE LYMPH NODES 3) MICRCOPIC PARAMETRIAL INVOLVEMENT B. INTERMEDIATE RISK FACTORS (recurrence rate 30% within 3 years) 1) LARGE TUMOR SIZE 2) CERVICAL STROMAL INVASION TO MIDDLE OR DEEP 1/3RD 3) LYMPHO-VASCULAR INVASION
20
21
Stage IV The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum. A bullous edema, as such, does not permit a case to be allotted to Stage IV. IVA Spread of the growth to adjacent organs
CONCURRENT CHEMORADIATION
22
STAGE IV B (Distant metastasis) CISPLATIN BASED CHEMOTHERAPY RADIATION DIRECTED TO PELVIS TO CONTROL SYMPTOMS AND LOCAL PELVIC DISEASE.
23
Hysterectomy
1) SUBTOTAL HST 2) Simple or extrafasical (????) ---- TYPE 1---- appropriate for stage Ia1 tumours without LVSI, who are not desirous of future fertility. 3) Modified radical HST (WERTHIEMS) --- TYPE 2 ---- appropriate for stage Ia1 (LVSI +), stage Ib onwards 4) RADICAL HST (MEIGS) ----- TYPE 3 ---- alternative to type 2 5) EXTENDED RADICAL ----- TYPE 4 (periureteral tissue, superior vesicle artery, of vagina) 6) EXTENDED RADICAL ----- TYPE 5 (portions of distal ureter and bladder are resected)
24
25
ROLE OF LYMPHADECTOMY
1. SENTINEL LN 2. SAMPLING 3. DEFINITIVE SURGICAL EXCISION 4. ADEQUACY 5. TREATMENT BASED ON (+) PARA-AORTIC LNS [ If during surgery for early stage, first search for para-aortic nodes --- if frozen section is negative --- go to pelvic nodes ---- sample and dissect along different HST subtypes.]
26
RADIATION
1) Can be used to treat all stages of cervical cancer. 2) Cure rates with radiation about 70% for stage I, 60% for stage II, 45% for stage III and 18% for IV. 3) EBRT + BRACHY 4) FOR stage IA1 & 2 ---- Brachy only 5) For all higher stages ----- Combination favoured as tumour load increases. 6)CURATIVE INTENT ----- STAGE SPECIFIC 7)PALLIATIVE DOSE ----- TO CONTROL SYMPTOMS
27
External irradiation is used to treat the whole pelvis and the parametria including the common iliac and para-aortic lymph nodes,
Central disease (cervix, vagina, and medial parametria) is primarily irradiated with intracavitary sources.
28
TIMING OF RADIATION
1) ADJUVANT RADIATION OR CHEMORADIATION. 2) RADICAL RADIATION OR CHEMORADIATION.
3) NEOADJUVANT . A. combination of preoperative irradiation and radical hysterectomy has been used in the treatment of patients with bulky stage IB and IIA tumors. B. Sometimes a LDR intracavitary insertion alone before surgery has been used (5,000 to 6,000 mgh). C. The rationale for use of an operation has been the alleged inability of irradiation to eradicate completely the metastatic tumor in the pelvic lymph nodes
29
31
PLANNING OF EBRT
DETERMINE THE DOSE TO BE PESCRIBED. Point A: LDR equivalent of 80-85 Gy (early stage disease, nonbulky Stage I-II) or 85-90 Gy (advanced stage, Stage IIIB or > 4 cm). Pelvic Sidewall: LDR equivalent of 50-55 Gy (early stage) or 55-60 Gy (advanced stage)
A. AVAILABILITY OF ENERGY SOURCE ---- Co60 or LINAC (6 -10MV) --- Box technique B. IFD ( > 18 cm ?) C. SHIELDING --- WIDTH ? ---- HOW DOES IT AFFECT THE BT DOSE ?
32
PLANNING OF EBRT
D. PARAMETRIAL BOOST E. PARA-AORTIC IRRADIATION [If para-aortic node metastases are present or suspected, patients are treated with 45 to 50 Gy to the para-aortic area plus a 5 to 10 Gy boost to enlarged lymph nodes through reduced lateral or rotational portals. With conventional techniques, the para-aortic lymph nodes are irradiated either with an extended field that includes both the para-aortic nodes and the pelvis or through a separate portal] F. ALTERED FRACTIONATION. G. 3D & IMRT IN CANCER OF CERVIX
33
Superior border of the pelvic portal should be at the L4-5 interspace to include all of the external iliac and hypogastric lymph nodes. This margin must be extended to the L3-4 interspace if common iliac nodal coverage is indicated.
The width of the pelvis at the level of the obturator fossae averaged 12.3 cm, and the distance between the femoral arteries at the level of the inguinal rings averaged 14.6 cm.
34
If there is no vaginal extension, the lower margin of the portal is at the inferior border of the obturator foramen. When there is vaginal involvement, the entire length of this organ should be treated down to the introitus 35
the posterior margin usually is designed to cover at least 50% of the rectum in stage IB tumors, and it should extend to the sacral hollow in patients with more advanced tumors
36
BRACHYTHERAPY
1. TYPES ---- INTRACAVITARY or INTERSTITIAL 2. RADIONUCLIDE ----- Cs 137, Ir -192. 3. DOSE RATE ---- LDR, PDR, HDR. 4. LOADING --- MANUAL/ REMOTE -- PRE / AFTERLOADING
INTRACAVITARY 1. Paris system 2. Stockholm system 3. Manchester system Todd & Meredith 4. Madison system (HDR)
37
INDICATIONS OF BRACHYTHERAPY INTRACAVITARY FOR ALL STAGES EITHER 1) AS STANDALONE (stage IA 2) COMBINATION WITH EBRT INTERSTITIAL 1. when parametrial extent of the tumor cannot be encompassed by
standard intracavitary brachytherapy. 2. A second indication is a narrow vagina not allowing the use of appropriate vaginal applicators toarrive at a sufficient dose distribution due to poor geometric conditions. 3. A third indication is represented by patients who had prior hysterectomy with the impossibility of a tandem placement. 4. A fourth indication includes patients with a recurrence inside an area previously irradiated restricting the use of further external irradiation.
38
Intracavitary brachytherapy
APPLICATORS A. (TANDEM OVOID [FULL / HALF] or B. RING or C. VAGINAL CYLINDER D. VIENNA applicator [intracavitary/ interstitial]
Tandem and ovoids variations 1. 2. 3. 4. 5. 6. FLETCHER FLECHTER SUIT FLETCHER SUIT DELCLOS FLETCHER WILLIAMSON WEEKS & MONTANA CT SCAN COMPATIBLE MRI COMPATIBLE
39
40
41
i. Always consider dose fractionation when converting the LDR to HDR. ii. For simplified calculation conversion factors are 0.54 to 0.6 for 3 to 5 HDR #s. iii. For higher number of #s (6-8), conversion factors is 0.75. iv. Radiobiological principle --- late tissue toxicity
DOSE LIMITATIONS
Keep dose to rectum and bladder points below 80% of dose to Point H (ABS recommendation) Or, maximum dose to rectum, 75 Gy (avg dose 68 Gy); bladder, 80 Gy (avg 70 Gy); vagina, 120-140 (avg 125 Gy).
42
43
44
45
46
47
48
49
51
52
53
LYMPHATIC TRAPEZOID
54
Ultrasound Computed tomography (CT) Magnetic resonance imaging (MRI) Positron emission tomography (PET) scans
The location of the uterus, cervix, and vagina, or the organs at risk (OAR), including the sigmoid, rectum, bladder, and small bowel.
55
In 2004, The American Brachytherapy Society (ABS) published guidelines for image-guided gynecologic brachytherapy.
56
In 2005, the Groupe Europe en Curietherapy European Society of Therapeutic Radiation Oncology (GEC-ESTRO) has advocated the implementation of MR evaluation in cervical cancer brachytherapy because of the superiority of MR imaging in identifying the cervix and residual tumor.
Haie-meder, 2005 Poetter, 2006
57
At a consensus conference in July 2005, the ABS and GEC-ESTRO leadership in gynecologic brachytherapy agreed to adopt the GEC-ESTRO guidelines and to advocate 3D image based planning for cervical cancer.
58
Clinical Target Volumes A first target related to the extent of GTV at diagnosis : with an intermediate dose prescribed to this target (60 Gy)Intermediate risk CTV A second target related to the extent of GTV at time of BT : taking into account tumor extent at diagnosis. with a high dose prescribed to this target (80-90 Gy) -High risk CTV
59
60
Intent : 80 to 90 + Gy total dose to CTV in definitive radiotherapy in advanced disease Dose comparable with dose to point A
61
Includes: Whole cervix Presumed tumor extension Clinical assessment Residual grey zones on MRI
62
CTV including safety margins with regard to dimensions of GTV at diagnosis TO CURE SIGNIFICANTT MICROSCOPIC DISEASE IN CERVIX CANCER, WHICH CORRESPONDS TO A DOSE OF AT LEAST Intent : 60 Gy total dose to CTV in definitive radiotherapy 60Gy. advanced disease in
63
64
RADIOTHERAPY
INDICATIONS Tumour bed at risk ,isolated unresectable residual , in recurrent disease within a previously radiated volume. Source- Electron or KV X-ray.
COMPLICATION OF RT
ACUTE
Rectal, Urinary, GI
CHRONIC
Bladder, Bowel, Spinal cord, Vagina.
66
CHEMORADIATION
67
Concomitant chemo-radiation
At an NCI sponsored consensus conference in April 1995 the panel concluded that there was no evidence that hydroxyurea or any other concomitant chemotherapy agent should be incorporated into standard practice
Only 3 years later a series of five randomized trials in a variety of cervical cancer stages conducted in the United States in the mid and late 1990s became mature.
68
69
70
Phase III trials with concurrent chemoradiotherapy in stage IB2-IVa CERVICAL CANCER: Dose of Cisplatin/m2
GOG 85 GOG 120 GOG 120 GOG 123 SWOG8797/ GOG 109 RTOG 9001 NCIC Cisplatin 50 mg day 1, 29 + FU infusion Cisplatin 50 mg day 1, 29 + FU infusion HU Cisplatin 40 mg weekly Cisplatin 40 mg weekly Cisplatin 70 mg day 1, 22 + FU infusion Cisplatin 70 mg day 1, 22 + FU infusion Cisplatin 40 mg, weekly
Green J, Cochrane Database Syst Rev 2005 Jul 2005 Green JA, THE LANCET Sept 2001
73
NEOADJUVANT CHEMOTHERAPY
NACT RATIONAL
1)Tumor size reduction may facilitate local therapy: radiotherapy or surgery 2)Possible transformation of inoperable tumor in radically resectable one 3)Treatment of micrometastatic disease 4)Response to NACT has been identified as an important prognostic factor
Benedetti-Panici E J Cancer 1998, Buda JCO 2005
74
NACT DISADVANTAGES
1)Delay in curative treatment (20-30% of patients who dont respond to NACT), 2)The development of radioresistant cellular clones, 3)Crossresistance with radiotherapy.
75
76
77
78
CHEMOTHERAPY- Contd.
Possible first line single agent therapy : Cisplatin(preferred), Carboplatin, Paclitaxel. Second line therapy : Bevacizumab / Docetaxel / 5FU / Gemcitabine / Iphosphamide / Irinotecan / Mitomycin / Topotecan / Pemetrexad / Vinoralbine.
SURVEILANCE
Interval H&P, Cervical / vaginal cytology every 3-6 months for 2 yrs,then every 6 months for 3-5 yrs, then annually. Chest X-ray annually. CBC,BUN, creatinine every 6 months. PET CT as clinically indicated. Patient education regarding symptoms.
RELAPSE:LOCAL
No prior RT or failure outside previousely treated field : Options are ---
RELAPSE : local
HISTORY OF PRIOR RT : CENTRAL DISEASE : Pelvic exenteretion +/IORT. NON CENTRAL DISEASE : Resection witth IORT, Chemotherapy, Best supportive care, Clinical trial.
RELAPSE : distant
Multiple sites or unresectable : Chemotherapy or best supportive care. Resectable metastasis : Resection +/-IORT,
85